RT Journal Article
SR Electronic
T1 Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1987
OP 1995
DO 10.21873/anticanres.15677
VO 42
IS 4
A1 MARTIN SVATON
A1 MONIKA BRATOVA
A1 LEONA KOUBKOVA
A1 ONDREJ FISCHER
A1 BOHUSLAV MELICHAR
A1 MICHAL HRNCIARIK
A1 DANIEL DOLEZAL
A1 ONDREJ BILEK
A1 JANA KREJCI
A1 MARIE DROSSLEROVA
A1 ZDENKA DLOUHA
A1 JIRI BLAZEK
A1 PETRA MAJKOVA
A1 LUCIE BROZOVA
A1 MAREK STASTNY
YR 2022
UL http://ar.iiarjournals.org/content/42/4/1987.abstract
AB Aim: This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens. Patients and Methods: The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treated adenocarcinomas in second and higher lines of treatment. In relation to objective response rate, progression-free interval, and overall survival, three comparisons of patient were made: A: Those treated in first line with cisplatin and pemetrexed versus carboplatin with paclitaxel or vinorelbine; B: treatment with cisplatin and pemetrexed versus carboplatin with paclitaxel/vinorelbine and bevacizumab; and C: treatment in previous lines with pemetrexed (first-line cisplatin and pemetrexed plus those treated in second line with pemetrexed) versus treatment with taxane (first-line carboplatin and paclitaxel only plus those treated with second-line docetaxel). Results: We observed no differences in objective response rate or progression-free survival between patients treated with the stated chemotherapeutic regimens. We observed a trend towards better overall survival for patients treated with carboplatin plus taxanes or vinorelbine with/without bevacizumab. Conclusion: From our overall survival data, a chemotherapeutic regimen of carboplatin plus taxanes or vinorelbine with/without bevacizumab might be a better partner for immunotherapy than a cisplatin and pemetrexed-based one.